Drugs / Eupenta
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04056728 | Sep 2019 → Oct 2020 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | LG Chem | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eupenta | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04056728 ↗ |
| Known as | EupentaTM Inj | “A Phase IV Study to Assess the Safety of EupentaTM Inj” NCT04056728 ↗ |
| Modality | Vaccine | “fully liquid pentavalent vaccine” NCT04056728 ↗ |